PROM1 and hepatocellular carcinoma: Hence, nanoparticle surface modification with CD133 antibody emerges as a highly beneficial strategy for enhancing therapeutic properties of the anti-cancer agents, rendering these NPs multifunctional and particularly well-suited for targeting CSCs in hepatocellular carcinoma.